Dear Friends and Colleagues,

we want to inform you about the developments and achievement of the Chronic Malignancies Working Party (CMWP) in 2015 and important events in 2016.

In 2015 we continued our mission to perform high quality educational event regarding disease specific topics of our Working Party.

In January 2015 we performed in Seville/Spain an exciting symposium “The role of stem cell transplantation in Multiple Myeloma and related diseases” in the era of novel drugs hosted by J. A. Perez-Simon.

On September 12, 2014 we organized a meeting in Helsinki “New developments in allogeneic SCT for MDS and MPN” hosted by L. Volin.

In 2016 we plan at least four further educational events (see “save the date”):
- Hamburg 30.01. (Myeloma)
- London 24.09. (MDS/MPN)
- Berlin 30.09. (Immunotherapy)
- Hamburg 03./04.11. (Relapse)

In 2015 the CMWP published 13 manuscripts in peer-reviewed journals such as Blood, Leukemia, Haematologica, BMT, and BBMT (see next page).

At international meetings such as ASH, EHA, EBMT or BMT Tandem meeting members of CMWP presented more than 30 oral or poster presentations.

Overall, in CMWP we have currently 10 non-interventional studies, 3 prospective EBMT sponsored or labelled studies ongoing and are working on more than 40 retrospective registry studies.

W’d like to encourage you to join our regular business meeting and educational events, submit proposals for retrospective and prospective studies, participate in lively discussions and exchange knowledge with colleagues and experts in the field.

The entire CMWP would like to express their gratefulness to all EBMT members and centers for their strong support in sending additional data for retrospective studies and including patients into ongoing trials.

We wish all of you and your families a Merry Christmas and a Happy New Year 2016 and hope to see you at one of our meetings!

SAVE THE DATE
+ + 2016 + +

January 29/30
Business Meeting (29.01.) and Educational Event, Hamburg (30.01.)
Host: N. Kröger
Topic: Options for relapse after autologous SCT in Multiple Myeloma.

April 4 / 5
Business Meeting during EBMT Annual Meeting,
Valencia/Spain

April 5
CMWP: Working Party Session (at EBMT Annual Meeting),
Valencia/Spain
Topic: Focus on Stem Cell Transplantation in Multiple Myeloma

September 23 - 24
Business Meeting and Educational Event, London/UK
Host: V. Potter, D. McLonal, R. Benjamin and K. Raj

September 30 - October 1
Educational Event in collaboration with Cellular Therapy and Immunobiology Working Party, Berlin
Topic: Come of age... Immunotherapy for Multiple Myeloma
Host: C. Bonini/N. Kröger

November 3 / 4
In collaboration with ASBMT/EBMT, Hamburg: 3. International Workshop of Prevention and Treatment of Relapse after Stem Cell Transplantation
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.
Bone Marrow Transplant. 2015 Dec;50(12):1542-50.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW, Garderet L, Kröger N.


Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myelo ma.

Donor Lymphocyte Infusions for Chronic Myeloid Leukaemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus Leukaemia Without Graft-versus-Host Disease?

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Efficacy and outcome of allogeneic transplantation in IgD and non-secretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Bone Marrow Transplant. 2015 Apr;50(4):505-10.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukaemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party.


Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.


Data management, statistician and subcommittees of CMWP

Marie Robin
SC Myelodysplastic Syndrome

Eduardo Olavarria
SC Myeloproliferative Neoplasms

Johannes Schetelig
SC Chronic Lymphocytic Leukemia

Laurent Garderet
SC Plasmacell-Disorders

Anja van Biezen
Data Management

Dimitris Ziagkos
Statistician

Simona Iacobelli
Statistician